SEHK:2616Biotechs
CStone Pharmaceuticals (SEHK:2616) Valuation After New Equity Awards And Board Changes
CStone Pharmaceuticals (SEHK:2616) has moved to refresh its governance and incentive structure, pairing a large equity award package for director and staff with board changes that bring new financial expertise and committee leadership.
See our latest analysis for CStone Pharmaceuticals.
These governance moves come as CStone’s share price trades at HK$5.43, with a 1-year total shareholder return of 132.05% contrasting with a 5-year total shareholder return of 52.03% and a softer 90-day share...